Dendritic cells loaded with exosomes derived from cancer stem cell‐enriched spheroids as a potential immunotherapeutic option
Open Access
- 25 February 2021
- journal article
- research article
- Published by Wiley in Journal of Cellular and Molecular Medicine
- Vol. 25 (7), 3312-3326
- https://doi.org/10.1111/jcmm.16401
Abstract
Cancer stem cells (CSCs) are responsible for therapeutic resistance and recurrence in colorectal cancer. Despite advances in immunotherapy, the inability to specifically eradicate CSCs has led to treatment failure. Hence, identification of appropriate antigen sources is a major challenge in designing dendritic cell (DC)‐based therapeutic strategies against CSCs. Here, in an in vitro model using the HT‐29 colon cancer cell line, we explored the efficacy of DCs loaded with exosomes derived from CSC‐enriched colonospheres (CSCenr‐EXOs) as an antigen source in activating CSC‐specific T‐cell responses. HT‐29 lysate, HT‐29‐EXOs and CSCenr lysate were independently assessed as separate antigen sources. Having confirmed CSCs enrichment in spheroids, CSCenr‐EXOs were purified and characterized, and their impact on DC maturation was investigated. Finally, the impact of the antigen‐pulsed DCs on the proliferation rate and also spheroid destructive capacity of autologous T cells was assessed. CSCenr‐EXOs similar to other antigen groups had no suppressive/negative impacts on phenotypic maturation of DCs as judged by the expression level of costimulatory molecules. Notably, similar to CSCenr lysate, CSCenr‐EXOs significantly increased the IL‐12/IL‐10 ratio in supernatants of mature DCs. CSCenr‐EXO‐loaded DCs effectively promoted T‐cell proliferation. Importantly, T cells stimulated with CSCenr‐EXOs disrupted spheroids' structure. Thus, CSCenr‐EXOs present a novel and promising antigen source that in combination with conventional tumour bulk‐derived antigens should be further explored in pre‐clinical immunotherapeutic settings for the efficacy in hampering recurrence and metastatic spread.Keywords
Funding Information
- Iran University of Medical Sciences (30098)
This publication has 85 references indexed in Scilit:
- Tumour‐derived exosomes as antigen delivery carriers in dendritic cell‐based immunotherapy for malignant mesotheliomaJournal of Extracellular Vesicles, 2013
- Dendritic cell-based in vitro assays for vaccine immunogenicityHuman Vaccines & Immunotherapeutics, 2012
- Cancer Stem Cell Vaccination Confers Significant Antitumor ImmunityCancer Research, 2012
- Dendritic Cell Based Tumor Vaccination in Prostate and Renal Cell Cancer: A Systematic Review and Meta-AnalysisPLOS ONE, 2011
- Translating Tumor Antigens into Cancer VaccinesClinical and Vaccine Immunology, 2011
- The application of exosomes as a nanoscale cancer vaccineInternational Journal of Nanomedicine, 2010
- Chemoresistant Colorectal Cancer Cells, the Cancer Stem Cell Phenotype, and Increased Sensitivity to Insulin-like Growth Factor-I Receptor InhibitionCancer Research, 2009
- Whole-cell cancer vaccination: from autologous to allogeneic tumor- and dendritic cell-based vaccinesCancer Immunology, Immunotherapy, 2008
- Translational Mini-Review Series on Vaccines:
Dendritic cell-based vaccines in renal cancerClinical and Experimental Immunology, 2007
- Mouse and human dendritic cell subtypesNature Reviews Immunology, 2002